Abstract: The present disclosure relates to the technical field of pyridine acetamide derivatives, and specifically relates to a pyridine acetamide derivative as a CDK inhibitor, a preparation method therefor and a use thereof. The pyridine acetamide derivative exhibits excellent CDK9/CDK7 kinase inhibitory activity, and can be used for preparing medications for treating cancers; and the cancers are particularly blood cancers, including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like, and solid tumors, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

Abstract: The present disclosure belongs to the technical field of polycyclic amide derivatives, in particular to a polycyclic amide derivative as a CDK9 inhibitor, a preparation method therefor and use thereof. The polycyclic amide derivative exhibits an excellent CDK9 kinase inhibitory activity, and can be used for preparing a medicine for treating cancers, wherein the cancers are especially hematological cancers, including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and solid tumors including breast cancer, prostate cancer, ovarian cancer, hepatocellular cancer, pancreatic cancer, renal cancer, gastric cancer, colorectal cancer, lung cancer, and the like.

Abstract: A pyrazolo[1,5-a]pyridine derivative, and a preparation method and medical use thereof are provided. The pyrazolo[1,5-a]pyridine derivative shown in general formula (I), a preparation method of the derivative, a pharmaceutically acceptable salt of the derivative, and use of the derivative or salt as a therapeutic agent, especially as a rearranged during transfection (RET) inhibitor, are provided.

Abstract: A compound represented by general formula (I), or a stereoisomer, a hydrate, a metabolite, a solvate, a pharmaceutically acceptable salt, a cocrystal, or a prodrug thereof, the preparation method thereof, and use thereof in the manufacture of a medicament for treatment of an airway obstructive disease, wherein the substituents are defined as in the specification.

Abstract: Provided is a pyridone or pyrimidone derivative(s) represented by general formula (I) and its preparation method and use. Substituents of the compound of general formula (I) are defined the same as in the specification.

Abstract: Provided is a pyridone or pyrimidone derivative(s) represented by general formula (I) and its preparation method and use. Substituents of the compound of general formula (I) are defined the same as in the specification.